央媒：“中国新”到“全球新”，我国创新药发展有哪些新动向

Core Insights - China's innovative pharmaceuticals are transitioning from imitation to independent innovation, with significant achievements in international markets [1][4][5] - The number of new drugs under development in China is projected to rank second globally by 2024, indicating a growing industry scale [3][4] - The domestic pharmaceutical industry is increasingly focusing on innovative drug development, with over 110 new drugs approved since the start of the 14th Five-Year Plan, reaching a market size of 100 billion yuan [4][9] Group 1: R&D and Clinical Trials - Domestic innovative drugs now account for over half of the clinical trials at major hospitals, reflecting a rapid increase in local drug development [1][3] - The Shanghai Zhangjiang Pharmaceutical Valley has become a hub for over a thousand biopharmaceutical companies, creating a complete ecosystem from drug discovery to commercialization [3][4] - Recent approvals include several innovative drugs that fill clinical gaps, such as treatments for rare diseases and chronic conditions [4][5] Group 2: International Expansion and Collaborations - Chinese pharmaceutical companies are increasingly engaging in overseas licensing agreements, with notable deals exceeding 60 billion yuan in total transaction value [7][8] - The internationalization of Chinese drugs is evident, with products like the PD-1 monoclonal antibody gaining approvals in nearly 40 countries [3][5] - The trend of expanding into biopharmaceuticals, including monoclonal antibodies and cell therapies, is expected to continue as global demand rises [8] Group 3: Policy Support and Funding - The Chinese government is implementing policies to streamline the approval process for innovative drugs, aiming to reduce review times to 30 working days [9][10] - Significant funding initiatives are being established to support pharmaceutical innovation, with investments exceeding 10 billion yuan in the sector [9][10] - Collaborative efforts between government and private sectors are being encouraged to enhance research and development capabilities in the pharmaceutical industry [10]